Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

被引：18

作者：

Templeton, I. E. ^{[1
]}

Chen, Y. ^{[1
]}

Mao, J. ^{[1
]}

Lin, J. ^{[2
]}

Yu, H. ^{[3
]}

Peters, S. ^{[4
]}

Shebley, M. ^{[5
]}

Varma, M. V. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Pfizer Inc, Groton, CT 06340 USA

[3] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA

[4] AstraZeneca, Molndal, Sweden

[5] AbbVie Inc, N Chicago, IL USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2016年 / 5卷 / 10期

关键词：

D O I：

10.1002/psp4.12110

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling. Three drugs with major circulating inhibitory metabolites (amiodarone, gemfibrozil, and sertraline) were systematically evaluated in addition to the literature review of recent examples. The application of PBPK modeling in drug interactions by inhibitory parent-metabolite pairs is described and guidance on strategic application is provided.

引用

页码：505 / 515

页数：11

共 50 条

[41] Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans
Min, Jee Sun
Kim, Doyun
Park, Jung Bae
Heo, Hyunjin
Bae, Soo Hyeon
Seo, Jae Hong
Oh, Euichaul
Bae, Soo Kyung
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2959 - 2972
[42] Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
Chiney, Manoj S.
Ng, Juki
Gibbs, John P.
Shebley, Mohamad
CLINICAL PHARMACOKINETICS, 2020, 59 (05) : 617 - 627
[43] Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
Yoon, Deok Yong
Lee, SeungHwan
Jang, In-Jin
Kim, Myeongjoong
Lee, Heechan
Kim, Seokuee
Kim, Bongtae
Song, Geun Seog
Rhee, Su-jin
PHARMACEUTICS, 2021, 13 (09)
[44] PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF SARPOGRELATE AND ITS APPLICATION FOR PREDICTION OF DRUG-DRUG INTERACTION IN HUMANS
Min, Jee Sun
Kim, Doyun
Park, Jung Bae
Heo, Hyunjin
Bae, Soo Hyeon
Bae, Soo Kyung
DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S53 - S53
[45] Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
Ji, Beihong
Liu, Shuhan
Xue, Ying
He, Xibing
Viet Hoang Man
Xie, Xiang-Qun
Wang, Junmei
DRUGS IN R&D, 2019, 19 (03) : 297 - 305
[46] Study and Prediction of Pharmacokinetic Drug-Drug Interactions
Hu, Zhe-Yi
CURRENT DRUG METABOLISM, 2014, 15 (08) : 759 - 760
[47] Practical Assessment of Clinical Drug-Drug Interactions in Drug Development Using Physiologically Based Pharmacokinetics Modeling
Shebley, Mohamad
Einolf, Heidi J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1326 - 1328
[48] Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin
Rodriguez-Vera, Leyanis
Yin, Xuefen
Almoslem, Mohammed
Romahn, Karolin
Cicali, Brian
Lukacova, Viera
Cristofoletti, Rodrigo
Schmidt, Stephan
PHARMACEUTICS, 2023, 15 (10)
[49] Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions
Cilliers, Cornelius
Howgate, Eleanor
Jones, Hannah M.
Rahbaek, Lisa
Tran, Jonathan Q.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (03) : 732 - 741
[50] Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model
Willemin, Marie-Emilie
Zannikos, Peter
Mannens, Geert
de Zwart, Loeckie
Snoeys, Jan
CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1115 - 1128

← 1 2 3 4 5 →